Caroline Seymour

OS was not improved with sigvotatug vedotin vs docetaxel in patients with pretreated, locally advanced, unresectable, or metastatic nonsquamous NSCLC.

Key Points From Sondak on CSCC Risk and Immunotherapy The NCCN risk classification system uniquely incorporates patient immune status alongside tumor features, making it Sondak's preferred framework for CSCC.

Key Takeaways FDA accepted a class 1 BLA resubmission for RP1 plus nivolumab in advanced melanoma, setting an August 2, 2026, goal date and notifying Replimune of a late-July advisory committee. IGNYTE enrolled unresectable stage IIIB–IV cutaneous melanoma with progression after ≥8 weeks of anti–PD-1 therapy, requiring measurable disease and ≥1 injectable ≥1 cm lesion; prior oncolytic therapy was excluded. Treatment used intratumoral RP1 (1×10⁶ then 1×10⁷ PFU/mL every 2 weeks) with nivolumab initiated cycle 2 (240 mg q2w then 480 mg q4w), with ORR as primary endpoint. Efficacy showed ORR ~33% in anti–PD-1–failed patients, median DOR up to 33.7 months, and 3-year OS 47.8% overall but 83.5% in responders, across key subgroups. Safety was consistent with oncolytic virus plus checkpoint inhibition, with grade 3/4 TRAEs 12.9% and rare grade 4 events including CRS and myocarditis, and no treatment-related deaths. SHOW MORE

Neoadjuvant Cemiplimab in HHI-Naive Head and Neck BCC: Key Findings

Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.

D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.

Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.

Atezolizumab did not yield a significant improvement in overall survival compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.